The COVID-19 MS Coalition-accelerating diagnostics, prognostics, and treatment.
2020
Rapid and comprehensive genetic
sequencing has shed light on the
origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and allowed timely implementation
of PCR tests to determine the presence
of viral RNA. PCR tests for SARS-CoV-2
are some way from being reliably
qualitative and will never indicate
how the disease might progress in
an individual. As COVID-19 becomes
endemic, there is a concomitant need
for accurate serological assays to detect
antibodies to SARS-CoV-2 antigens and
ultimately tests for prognostic markers
to target treatment options.1,2 With this
considerable genetic insight, and the
emerging structural information, comes
associated questions regarding the
molecular descriptors that contribute
to disease progression, especially when
we consider spread across different
populations. The power of mass spectrometry to generate rapid, precise, and
reproducible diagnostic information that
complements genomic information and
accelerates our understanding of the
disease, is now becoming a reality.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
36
Citations
NaN
KQI